TrialCancer2016

Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.

Anne M Noonan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.